Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review

BACKGROUND: Detailed prevalence estimates of BRAFV600 mutations and BRAF inhibitor (BRAFi) treatment responses in V600-mutant glioma will inform trial development. METHODS: Our systematic review analyzed overall prevalence of BRAFV600 mutations in glioma and BRAFi treatment response. RESULTS: Based...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrews, Lily J, Thornton, Zak A, Saincher, Saanwalshah S, Yao, Ian Y, Dawson, Sarah, McGuinness, Luke A, Jones, Hayley E, Jefferies, Sarah, Short, Susan C, Cheng, Hung-Yuan, McAleenan, Alexandra, Higgins, Julian P T, Kurian, Kathreena M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Metadata Analysis/Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972326/
https://www.ncbi.nlm.nih.gov/pubmed/34718782
http://dx.doi.org/10.1093/neuonc/noab247

Ejemplares similares

Ejemplares similares